Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | F9 | P00740 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3191877 | 0.88 | HDAC1 (0.44) | HDAC1MAPTPOLBRAB9AS1PR5 | |
| SCHEMBL3203077 | 0.78 | EPHX2 (0.50) | MAPTPOLBRAB9ATP53LMNA | |
| SCHEMBL3196705 | 0.76 | ESR1 (0.44) | HDAC1MAPTTP53F9SMN1; SMN2 | |
| SCHEMBL3205824 | 0.74 | F10 (0.45) | POLBRAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL25444276 | 0.74 | DAO (0.42) | CYP2A6ADRB2SMN1; SMN2 | |
| SCHEMBL3205877 | 0.73 | PLAU (0.50) | MAPTPOLBRAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL3203065 | 0.73 | HDAC1 (0.42) | HDAC1KDM4E | |
| SCHEMBL3193606 | 0.71 | TRPV1 (0.43) | MAPTRAB9ATP53SMN1; SMN2 | |
| SCHEMBL3196195 | 0.71 | PLAU (0.40) | MAPTPOLBRAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL25444292 | 0.71 | DAO (0.40) | RAB9ACYP2A6ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120802-A1 | Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production | MAKOVEC FRANCESCO | 2010-05-13 | — | — | US | disclosed |
| US-7674809-B2 | Anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM S.P.A. (IT) | 2010-03-09 | — | — | US | disclosed |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM SPA | 2005-09-08 | — | — | US | disclosed |
| EP-1571142-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | Rottapharm S.p.A. (IT) | 2005-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120802-A1 | Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production | NOS3, NOS1, NOS2 | HDAC1 485/4885MAPT 4542/4885POLB 3621/4885 |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | NOS3, NOS1, NOS2 | HDAC1 485/4885MAPT 4542/4885POLB 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.